SMC: Zoledronic acid (Aclasta) not recommended for treatment of osteoporosis in men

This is the advice published by the Scottish Medicines Consortium about the use of zoledronic acid for the treatment of osteoporosis in men.

ADVICE: in the absence of a submission from the holder of the marketing authorisation.
zoledronic acid 5mg (Aclasta®) is not recommended for use within NHSScotland for the
treatment of osteoporosis in men at increased risk of fracture, including those with a recent
low-trauma hip fracture.
The holder of the marketing authorisation has not made a submission to SMC regarding this
product in this indication. As a result we cannot recommend its use within NHSScotland.

Source: Scottish Medicines Consortium. Drug advice: Zoledronic acid (Aclasta)

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations. 
  • Practical tips for mental health professionals.




Are you a visual learner interested in learning psychopharmacology? Click here to get our videos